YOLFTbeta
34

KoBioLabs Inc

348150 · KQ · Healthcare / Biotechnology

2,690.00KRW+10.00 (+0.37%)

Price History

Full chart

Market Stats

Previous Close2,680.00
Open2,650.00
Day Range2,650.00 – 2,745.00
52-Week Range2,310.00 – 8,730.00
Volume18.36K
Market Cap58.06B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.14
50-Day Avg2,950.80
200-Day Avg4,403.65

About

KoBioLabs, Inc. provides microbiome therapeutics for metabolic, immune, and brain diseases. The company was founded in 2014 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Han Seung Lee Ph.D.
  • Employees51
  • Headquarters1 Gwanak-ro, Seoul, South Korea, 08826, Korea
  • Websitehttps://kobiolabs.com

Leadership

  • Mr. Han Seung Lee Ph.D.Chief Executive Officer
  • Mr. GwangPyo KoFounder & CVO
  • Mr. Hyunkyu LimCFO & Head of Management Support Division
  • Dr. Sang Kyun Lim Ph.D.CTO & Chief Research Officer
  • Mr. Yong Won Shin Ph.D.Head of CMC Department
  • Mr. Hyungjin Lee M.B.A.Chief Strategy Officer & Head of Strategic Planning
  • Ms. Yurn-Su SongHead of Clinical Development
  • Dr. Hyun Ju You Ph.D.Head of Microbiome Center
  • Ms. Sangmi NamHead of Business Department
  • Ms. Heekyeong JeonHead of Business Development

Financials

Income Statement

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue64.16M576.52M4.59B2.89B11.61B33.14B68.36B69.29B
Growth (%)-+798.53%+696.42%-36.98%+301.12%+185.54%+106.28%+1.36%
Cost of Revenue42.66M288.66M1.95B984.24M3.58B9.41B21.54B18.24B
Gross Profit21.50M287.86M2.64B1.91B8.02B23.73B46.82B51.05B
Gross Margin33.51%49.93%57.54%65.98%69.11%71.61%68.49%73.68%
Operating Expense2.37B7.64B14.98B18.25B28.31B42.17B53.26B60.70B
Operating Income-2.35B-7.35B-12.34B-16.34B-20.29B-18.44B-6.44B-9.65B
Operating Margin-3667.97%-1275.22%-268.68%-564.90%-174.80%-55.64%-9.43%-13.93%
EBITDA-----20.44B-11.64B-441.77M-3.66B
EBITDA Margin-----176.11%-35.11%-0.65%-5.28%
Net Income-8.38B-44.07B-55.07B-15.38B-21.92B-13.85B-5.30B-6.33B
Net Income Margin-13064.31%-7643.57%-1199.45%-531.63%-188.89%-41.80%-7.75%-9.14%
R&D--8.88B12.50B14.20B14.26B6.91B7.57B
R&D as % of Total Revenue--193.44%431.89%122.33%43.04%10.10%10.93%
Interest Expense00708.11M152.59M1.68B1.53B1.16B512.40M
Interest Expense % of Total Revenue0.00%0.00%15.42%5.27%14.50%4.62%1.69%0.74%

Balance Sheet

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets9.29B35.32B58.54B105.29B123.93B114.62B102.10B91.26B
Total Liabilities21.16B88.95B3.15B14.70B46.61B52.80B64.18B41.99B
Total Equity-11.88B-53.62B55.39B90.59B77.32B44.95B37.92B32.40B
Cash3.82B1.28B40.63B52.69B10.43B10.05B5.69B4.59B
Total Debt-72.99M57.10M-----
Net Debt----3.03B7.82B10.60B8.82B

Cash Flow

Currency: KRW2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.98B-5.71B-12.77B-12.48B-16.56B-13.83B-4.36B-5.78B
Investing Cash Flow5.11B-27.43B20.99B-31.15B-61.81B8.19B6.43B-
Financing Cash Flow44.72M30.60B31.05B55.74B36.31B4.05B-6.51B-
Capital Expenditure295.88M290.16M124.98M5.55B14.76B15.56B1.65B552.91M
Free Cash Flow--10.94B-13.05B-18.92B-28.57B-29.39B-6.00B-6.34B
FCF to OCF-191.59%102.16%151.59%172.58%212.50%137.80%109.56%

Earnings

Report DateMay 17, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Nov 14, 2022Mar 21, 2023Mar 31, 2023Aug 14, 2023Nov 14, 2023Mar 20, 2024May 3, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----------------------
EPS Actual-189.67-276.63-264.95-232.32-234.79-372.73-251.07-444.96-197.07-87.20-171.16-292.68-115.84-6.57-82.93-69.68-134.21-140.296.60-58.350.06-195.69
Surprise----------------------
Timing------After-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours---------

Key Statistics & Ratios

Market Cap58.06B
Enterprise Value20.46B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.77
Price / Book1.80
Revenue (TTM)75.41B
Gross Profit (TTM)56.49B
EBITDA-5.27B
Profit Margin-6.37%
Operating Margin-9.23%
Return on Equity-10.02%
Return on Assets-5.47%
Shares Outstanding19.42M
Shares Float13.57M
Beta0.14
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%